Patrick Van Winkle1, Raoul Burchette2, Raymond Kim3, Rukmani Raghunathan4, Naveen Qureshi5. 1. Pediatric Hospitalist at the Anaheim Medical Center in CA. patrick.j.vanwinkle@kp.org. 2. Statistician for Kaiser Permanente Southern California Research and Evaluation in Pasadena. raoul.j.burchette@kp.org. 3. Research Assistant for Kaiser Permanente Southern California Research and Evaluation in Pasadena. rwhkim@gmail.com. 4. Pediatric Oncologist in the Department of Pediatric Hematology and Oncology at the Anaheim Medical Center in CA. rukmani.raghunathan@kp.org. 5. Pediatric Oncologist in the Department of Pediatric Hematology and Oncology at the Anaheim Medical Center in CA. naveen.a.qureshi@kp.org.
Abstract
CONTEXT: Children with acute lymphoblastic leukemia (ALL) in first complete remission (CR1) experience hypogammaglobulinemia and are at risk of sepsis during maintenance chemotherapy. Intravenous immunoglobulin (IVIG) has been used to try to circumvent this risk, but no data exist regarding its safety and prevalence in a health maintenance organization. OBJECTIVE: To evaluate the prevalence and safety of IVIG in children with ALL in CR1 during maintenance chemotherapy. DESIGN: A multicenter, retrospective cohort study of consecutive children with ALL in CR1 during maintenance chemotherapy from 2008 to 2014. Groups treated with or without IVIG were compared using nonparametric statistics. Multivariate logistic regression involved all variables available before maintenance therapy began. RESULTS: One hundred eighteen patients were included (53% males), aged 9 months to 19 years. Thirty of 31 patients (97%) who had immunoglobulins analyzed before IVIG were hypogammaglobulinemic. Thirty-six patients (30%) received IVIG during maintenance chemotherapy. Patients received an average of 10.5 IVIG doses (range = 1-31). Ninety-seven percent of doses were administered without a transfusion reaction. Other factors associated with IVIG use were prior double-delayed intensification (odds ratio = 5.36, 95% confidence interval = 1.3-27.49, p = 0.026) and episodes of bacteremia or fungemia before maintenance chemotherapy (odds ratio = 3.04, 95% confidence interval = 1.25-7.51, p = 0.015). CONCLUSION: Use of IVIG in children with ALL in CR1 with hypogammaglobulinemia occurred in approximately 30% of patients and was well tolerated. Administration of IVIG significantly correlated with a history of double-delayed intensification and prior bacteremia or fungemia.
CONTEXT: Children with acute lymphoblastic leukemia (ALL) in first complete remission (CR1) experience hypogammaglobulinemia and are at risk of sepsis during maintenance chemotherapy. Intravenous immunoglobulin (IVIG) has been used to try to circumvent this risk, but no data exist regarding its safety and prevalence in a health maintenance organization. OBJECTIVE: To evaluate the prevalence and safety of IVIG in children with ALL in CR1 during maintenance chemotherapy. DESIGN: A multicenter, retrospective cohort study of consecutive children with ALL in CR1 during maintenance chemotherapy from 2008 to 2014. Groups treated with or without IVIG were compared using nonparametric statistics. Multivariate logistic regression involved all variables available before maintenance therapy began. RESULTS: One hundred eighteen patients were included (53% males), aged 9 months to 19 years. Thirty of 31 patients (97%) who had immunoglobulins analyzed before IVIG were hypogammaglobulinemic. Thirty-six patients (30%) received IVIG during maintenance chemotherapy. Patients received an average of 10.5 IVIG doses (range = 1-31). Ninety-seven percent of doses were administered without a transfusion reaction. Other factors associated with IVIG use were prior double-delayed intensification (odds ratio = 5.36, 95% confidence interval = 1.3-27.49, p = 0.026) and episodes of bacteremia or fungemia before maintenance chemotherapy (odds ratio = 3.04, 95% confidence interval = 1.25-7.51, p = 0.015). CONCLUSION: Use of IVIG in children with ALL in CR1 with hypogammaglobulinemia occurred in approximately 30% of patients and was well tolerated. Administration of IVIG significantly correlated with a history of double-delayed intensification and prior bacteremia or fungemia.
Authors: Cornelis M van Tilburg; Elisabeth A M Sanders; Elisabeth E Nibbelke; Rob Pieters; Tom Revesz; Paul Westers; Tom F W Wolfs; Marc B Bierings Journal: Br J Haematol Date: 2011-01-11 Impact factor: 6.998
Authors: Cornelis M van Tilburg; Marc B Bierings; Guy A M Berbers; Tom F W Wolfs; Rob Pieters; Andries C Bloem; Elisabeth A M Sanders Journal: Pediatr Blood Cancer Date: 2011-07-25 Impact factor: 3.167
Authors: Karen Thudium Mueller; Stephan A Grupp; Shannon L Maude; John E Levine; Michael A Pulsipher; Michael W Boyer; Keith J August; G Doug Myers; Constantine S Tam; Ulrich Jaeger; Stephen Ronan Foley; Peter Borchmann; Stephen J Schuster; Edmund K Waller; Rakesh Awasthi; Bernd Potthoff; Andy Warren; Edward R Waldron; Fraser McBlane; Andrea Chassot-Agostinho; Theodore W Laetsch Journal: Blood Adv Date: 2021-12-14
Authors: Cassandra S Lange; April Rahrig; Sandra K Althouse; Robert P Nelson; Sandeep Batra Journal: J Adolesc Young Adult Oncol Date: 2020-07-13 Impact factor: 1.757